CBL8 Antibody

Clarification of Terminology

• c-Cbl Antibodies: Target the Casitas B-lineage lymphoma proto-oncogene, a ubiquitin ligase involved in protein degradation and signaling regulation .

• CCR8 Antibodies: Target the C-C chemokine receptor type 8, a GPCR implicated in cancer immunotherapy .

A typographical error ("CBL8" vs. "CCR8") is plausible given the similarity in nomenclature and the prominence of CCR8 in recent oncology research.

c-Cbl Antibodies: Key Research Data

c-Cbl antibodies are widely used in oncology and immunology research. Below are critical findings from the literature:

Table 1: c-Cbl Antibody Characteristics

Functional Insights:

• c-Cbl antibodies inhibit oncogenic signaling by tagging activated tyrosine kinases (e.g., EGFR) for proteasomal degradation .

• Preclinical studies show c-Cbl antibodies sensitize lymphoma cells to cytotoxic agents like cisplatin and TNF-α .

CCR8 Antibodies: Therapeutic Relevance in Oncology

If the query intended "CCR8 Antibody," recent advancements are significant:

Table 2: CCR8 Antibody Development

Research Findings:

• CCR8 antibodies deplete intratumoral regulatory T cells (Tregs), enhancing anti-tumor immunity .

• Structural studies reveal CCR8-antibody complexes block chemokine binding via extracellular loop interactions .

Comparative Analysis of c-Cbl vs. CCR8 Antibodies